High-throughput screening (HTS) remains a foundational technology in early drug discovery, responsible for identifying approximately one-third of today’s clinical candidates....
Continue Reading
High-throughput screening (HTS) remains critical for early drug discovery, yet traditional biochemical assays and specialized techniques such as affinity selection...
Continue Reading
Despite major advances in small molecule drug development, most disease-relevant proteins remain beyond the reach of conventional therapeutics. Molecular glues...
Continue Reading
From hematologic malignancies to solid tumors Introduction: Amid a surge of advancements in immunotherapy, T cell engager (TCE) therapy has...
Continue Reading
Molecular glues are molecules that can encourage two proteins to interact when they otherwise may not. As a consequence, they...
Continue Reading
Target deconvolution, particularly when paired with proteomics techniques, plays a crucial role in drug discovery and target identification. By using...
Continue Reading
Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...
Continue Reading
Introduction: RNA-based therapies are a frontier in biomedicine, with the potential to fundamentally change treatments for a wide range of...
Continue Reading
Overview of AAV Gene Therapy: Evolution and Current Landscape Adeno-associated virus (AAV) is a non-enveloped, replication-defective single-stranded DNA virus belonging...
Continue Reading
